NCT02981368 - Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer | Biotech Hunter

Enrollment

385

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

July 31, 2018

Study Completion Date

July 31, 2018

Conditions

Prostate Cancer

Interventions

DRUG

18F-DCFPyL Injection

A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL

DIAGNOSTIC_TEST

PET/CT imaging

PET/CT imaging will be acquired 1-2 hours post-PyL injection

Trial Locations (10)

Memorial Sloan Kettering Cancer Center, New York

Johns Hopkins University, Baltimore

University of Michigan Cancer Center, Ann Arbor

University of Chicago, Chicago

Washington University Mallinckrodt Institute of Radilogy, St Louis

University of California at San Francisco (UCSF) - Mt. Zion Hospital, San Francisco

Yale University Department of Radiology and Biomedical Imaging, New Haven

Dana Farber Cancer Institute, Boston

Jewish General Hospital, Montreal

Centre Hospitalier Universitaire de Quebec (CHUQ), Québec

All Listed Sponsors

lead

Progenics Pharmaceuticals, Inc.

INDUSTRY